Workflow
“常温乳酸菌第一股”受罚背后:上市五年净利润首度亏损 押宝益生菌难掩业绩颓势

Core Viewpoint - Junyao Health, known as the "first stock of ambient lactic acid bacteria," has recently faced penalties for failing to timely announce a profit warning for its 2024 annual performance, marking its first annual loss since its listing in 2020 [1][4][5]. Financial Performance - In 2024, Junyao Health reported a revenue of 1.458 billion yuan, a year-on-year decline of 10.77% [6]. - The company recorded a net profit loss attributable to shareholders of 29.1164 million yuan for 2024, primarily due to impairment provisions totaling 3.643 million yuan for goodwill, 1.276 million yuan for inventory, and 3.660 million yuan for credit losses [4][5]. - In the first quarter of 2025, the company achieved a revenue of 401 million yuan, a year-on-year increase of 1.41%, but the net profit attributable to shareholders decreased by 58.29% to 10.91 million yuan [6]. Stock Performance - Despite the poor financial performance, Junyao Health's stock price surged over 70% in less than two weeks, from 6.35 yuan per share to 10.95 yuan per share [2][7]. Business Strategy and Challenges - The company has been diversifying into new business areas such as bottled water, probiotics, and supply chain management, but these efforts have not yet yielded significant results [9][11]. - The probiotics segment, which is a key focus for the company, has faced challenges including low industry entry barriers, intense price competition, and changing consumer preferences towards low-sugar products [10]. - The supply chain business, acquired in 2022, failed to meet its revenue and profit commitments, contributing to the company's financial difficulties [11].